These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 38187038

  • 41. A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer.
    Paraghamian SE, Qiu J, Hawkins GM, Zhao Z, Sun W, Fan Y, Zhang X, Suo H, Hao T, Prabhu VV, Allen JE, Zhou C, Bae-Jump V.
    Cancer Biol Ther; 2023 Dec 31; 24(1):2202104. PubMed ID: 37069726
    [Abstract] [Full Text] [Related]

  • 42. Upregulation of p75NTR by Histone Deacetylase Inhibitors Sensitizes Human Neuroblastoma Cells to Targeted Immunotoxin-Induced Apoptosis.
    Dedoni S, Olianas A, Manconi B, Collu M, Tuveri B, Vincis ME, Olianas MC, Onali P.
    Int J Mol Sci; 2022 Mar 31; 23(7):. PubMed ID: 35409209
    [Abstract] [Full Text] [Related]

  • 43. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
    Wang G, Edwards H, Caldwell JT, Buck SA, Qing WY, Taub JW, Ge Y, Wang Z.
    PLoS One; 2013 Mar 31; 8(9):e76662. PubMed ID: 24098799
    [Abstract] [Full Text] [Related]

  • 44. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat.
    Martin BP, Frew AJ, Bots M, Fox S, Long F, Takeda K, Yagita H, Atadja P, Smyth MJ, Johnstone RW.
    Int J Cancer; 2011 Jun 01; 128(11):2735-47. PubMed ID: 20715169
    [Abstract] [Full Text] [Related]

  • 45. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
    Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA, Banks KM, Haynes NM, Gangatirkar P, Stanley K, Bolden JE, Takeda K, Yagita H, Secrist JP, Smyth MJ, Johnstone RW.
    Proc Natl Acad Sci U S A; 2008 Aug 12; 105(32):11317-22. PubMed ID: 18685088
    [Abstract] [Full Text] [Related]

  • 46. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A, Flahaut M, Bourloud KB, Auderset K, Meier R, Joseph JM, Gross N.
    BMC Cancer; 2006 Aug 24; 6():214. PubMed ID: 16930472
    [Abstract] [Full Text] [Related]

  • 47. The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies.
    Singh A, Patel P, Jageshwar, Patel VK, Jain DK, Kamal M, Rajak H.
    Curr Cancer Drug Targets; 2018 Aug 24; 18(8):720-736. PubMed ID: 28669336
    [Abstract] [Full Text] [Related]

  • 48. HDAC inhibitors Panobinostat and Romidepsin enhance tax transcription in HTLV-1-infected cell lines and freshly isolated patients' T-cells.
    Schnell AP, Kohrt S, Aristodemou A, Taylor GP, Bangham CRM, Thoma-Kress AK.
    Front Immunol; 2022 Aug 24; 13():978800. PubMed ID: 36052071
    [Abstract] [Full Text] [Related]

  • 49. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
    Lopez G, Torres K, Liu J, Hernandez B, Young E, Belousov R, Bolshakov S, Lazar AJ, Slopis JM, McCutcheon IE, McConkey D, Lev D.
    Cancer Res; 2011 Jan 01; 71(1):185-96. PubMed ID: 21084276
    [Abstract] [Full Text] [Related]

  • 50. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
    Amnekar RV, Khan SA, Rashid M, Khade B, Thorat R, Gera P, Shrikhande SV, Smoot DT, Ashktorab H, Gupta S.
    World J Gastroenterol; 2020 Feb 14; 26(6):598-613. PubMed ID: 32103870
    [Abstract] [Full Text] [Related]

  • 51. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
    Norris RE, Adamson PC, Nguyen VT, Fox E.
    Pediatr Blood Cancer; 2014 Jan 14; 61(1):145-50. PubMed ID: 24038812
    [Abstract] [Full Text] [Related]

  • 52. Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.
    Lu HK, Gray LR, Wightman F, Ellenberg P, Khoury G, Cheng WJ, Mota TM, Wesselingh S, Gorry PR, Cameron PU, Churchill MJ, Lewin SR.
    PLoS One; 2014 Jan 14; 9(11):e113341. PubMed ID: 25409334
    [Abstract] [Full Text] [Related]

  • 53. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
    Kaletsch A, Pinkerneil M, Hoffmann MJ, Jaguva Vasudevan AA, Wang C, Hansen FK, Wiek C, Hanenberg H, Gertzen C, Gohlke H, Kassack MU, Kurz T, Schulz WA, Niegisch G.
    Clin Epigenetics; 2018 Jul 31; 10(1):100. PubMed ID: 30064501
    [Abstract] [Full Text] [Related]

  • 54. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
    Yaseen A, Chen S, Hock S, Rosato R, Dent P, Dai Y, Grant S.
    Mol Pharmacol; 2012 Dec 31; 82(6):1030-41. PubMed ID: 22923501
    [Abstract] [Full Text] [Related]

  • 55. Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis via synergistic upregulation of ALAS1 expression.
    Chen CP, Chen K, Feng Z, Wen X, Sun H.
    Acta Pharm Sin B; 2019 Sep 31; 9(5):937-951. PubMed ID: 31649844
    [Abstract] [Full Text] [Related]

  • 56. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
    Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD.
    Invest New Drugs; 2013 Aug 31; 31(4):845-57. PubMed ID: 23299388
    [Abstract] [Full Text] [Related]

  • 57. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
    Palani CD, Beck JF, Sonnemann J.
    Invest New Drugs; 2012 Feb 31; 30(1):25-36. PubMed ID: 20680659
    [Abstract] [Full Text] [Related]

  • 58. Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines.
    Unland R, Clemens D, Heinicke U, Potratz JC, Hotfilder M, Fulda S, Wardelmann E, Frühwald MC, Dirksen U.
    Anticancer Drugs; 2015 Sep 31; 26(8):843-51. PubMed ID: 26053276
    [Abstract] [Full Text] [Related]

  • 59. Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.
    Jazirehi AR, Arle D.
    Am J Clin Exp Immunol; 2013 Sep 31; 2(1):55-74. PubMed ID: 23885325
    [Abstract] [Full Text] [Related]

  • 60. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
    Matthews GM, Lefebure M, Doyle MA, Shortt J, Ellul J, Chesi M, Banks KM, Vidacs E, Faulkner D, Atadja P, Bergsagel PL, Johnstone RW.
    Cell Death Dis; 2013 Sep 12; 4(9):e798. PubMed ID: 24030150
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.